利用冷大气等离子治疗轻度丘疹性痤疮--随机、对照、双盲试验研究

IF 3.7 4区 医学 Q1 DERMATOLOGY Dermatologic Therapy Pub Date : 2025-03-03 DOI:10.1155/dth/4228323
Melvin Bae, Jürgen Lademann, Martina C. Meinke, Björn Meder, Christoph Geilen
{"title":"利用冷大气等离子治疗轻度丘疹性痤疮--随机、对照、双盲试验研究","authors":"Melvin Bae,&nbsp;Jürgen Lademann,&nbsp;Martina C. Meinke,&nbsp;Björn Meder,&nbsp;Christoph Geilen","doi":"10.1155/dth/4228323","DOIUrl":null,"url":null,"abstract":"<div>\n <p>Acne is a common disease worldwide, predominantly occurring in teenagers. Commonly prescribed therapies often cause adverse effects and in case of antibiotics bare the risk of developing resistances. Cold atmospheric plasma (CAP) is a well-tolerable, physical treatment method, which is well established in the treatment of chronic wounds since it provides bactericidal and wound healing properties. Our aim was to evaluate the efficacy and safety of CAP as a potential add-on therapy for mild acne papulopustulosa in a randomized controlled, double-blind pilot study. Forty participants were randomized into two arms of 20 each. Both groups self-applied 0.1% of adapalene cream daily and received weekly skin-cleansing by a physician combined with either CAP verum-device treatments or placebo-device applications instead. The endpoint of the treatment segment was at 6, and follow-up was at 10 weeks. The co-primary endpoints total inflammatory lesion count (TILC) and acne-specific Investigator Global Assessment (IGA) score as well as secondary endpoints sebumetry, total porphyrin count (TPC) reflecting <i>Cutibacterium acnes</i> colonization, and occurrence of adverse events (AEs) were measured from baseline until follow-up, while the Acne-specific Quality of Life (AQOL) questionnaire was assessed at baseline and endpoint. TILC decreased greater in the verum versus control group from baseline (45.8 vs. 49.4) toward endpoint (22.1 vs. 38.6; <i>p</i> = 0.07) to follow-up (16.5 vs. 28.7; <i>p</i> = 0.48), matched by the IGA score with similarly greater improvement in the verum versus control group from baseline (2.3 vs. 2.6) to endpoint (1.3 vs. 2.3; <i>p</i> &lt;  0.001) until follow-up (1.0 vs. 1.9; <i>p</i> = 0.006). Sebumetry, TPC, and AQOL scores decreased more during treatment and in the verum group. AE occurred less frequently in the verum group without serious AE reported overall (all <i>p</i> &lt; 0.05). Conclusively, CAP proved to be an efficient and well-tolerable add-on therapy for the treatment of mild acne papulopustulosa.</p>\n <p><b>Trial Registration:</b> German Registry of Clinical Trials: DRKS00032416</p>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4228323","citationCount":"0","resultStr":"{\"title\":\"Therapeutic Use of Cold Atmospheric Plasma for the Treatment of Mild Acne Papulopustulosa—A Randomized, Controlled, Double-Blind Pilot Study\",\"authors\":\"Melvin Bae,&nbsp;Jürgen Lademann,&nbsp;Martina C. Meinke,&nbsp;Björn Meder,&nbsp;Christoph Geilen\",\"doi\":\"10.1155/dth/4228323\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p>Acne is a common disease worldwide, predominantly occurring in teenagers. Commonly prescribed therapies often cause adverse effects and in case of antibiotics bare the risk of developing resistances. Cold atmospheric plasma (CAP) is a well-tolerable, physical treatment method, which is well established in the treatment of chronic wounds since it provides bactericidal and wound healing properties. Our aim was to evaluate the efficacy and safety of CAP as a potential add-on therapy for mild acne papulopustulosa in a randomized controlled, double-blind pilot study. Forty participants were randomized into two arms of 20 each. Both groups self-applied 0.1% of adapalene cream daily and received weekly skin-cleansing by a physician combined with either CAP verum-device treatments or placebo-device applications instead. The endpoint of the treatment segment was at 6, and follow-up was at 10 weeks. The co-primary endpoints total inflammatory lesion count (TILC) and acne-specific Investigator Global Assessment (IGA) score as well as secondary endpoints sebumetry, total porphyrin count (TPC) reflecting <i>Cutibacterium acnes</i> colonization, and occurrence of adverse events (AEs) were measured from baseline until follow-up, while the Acne-specific Quality of Life (AQOL) questionnaire was assessed at baseline and endpoint. TILC decreased greater in the verum versus control group from baseline (45.8 vs. 49.4) toward endpoint (22.1 vs. 38.6; <i>p</i> = 0.07) to follow-up (16.5 vs. 28.7; <i>p</i> = 0.48), matched by the IGA score with similarly greater improvement in the verum versus control group from baseline (2.3 vs. 2.6) to endpoint (1.3 vs. 2.3; <i>p</i> &lt;  0.001) until follow-up (1.0 vs. 1.9; <i>p</i> = 0.006). Sebumetry, TPC, and AQOL scores decreased more during treatment and in the verum group. AE occurred less frequently in the verum group without serious AE reported overall (all <i>p</i> &lt; 0.05). Conclusively, CAP proved to be an efficient and well-tolerable add-on therapy for the treatment of mild acne papulopustulosa.</p>\\n <p><b>Trial Registration:</b> German Registry of Clinical Trials: DRKS00032416</p>\\n </div>\",\"PeriodicalId\":11045,\"journal\":{\"name\":\"Dermatologic Therapy\",\"volume\":\"2025 1\",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4228323\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologic Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/dth/4228323\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/4228323","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Therapeutic Use of Cold Atmospheric Plasma for the Treatment of Mild Acne Papulopustulosa—A Randomized, Controlled, Double-Blind Pilot Study

Acne is a common disease worldwide, predominantly occurring in teenagers. Commonly prescribed therapies often cause adverse effects and in case of antibiotics bare the risk of developing resistances. Cold atmospheric plasma (CAP) is a well-tolerable, physical treatment method, which is well established in the treatment of chronic wounds since it provides bactericidal and wound healing properties. Our aim was to evaluate the efficacy and safety of CAP as a potential add-on therapy for mild acne papulopustulosa in a randomized controlled, double-blind pilot study. Forty participants were randomized into two arms of 20 each. Both groups self-applied 0.1% of adapalene cream daily and received weekly skin-cleansing by a physician combined with either CAP verum-device treatments or placebo-device applications instead. The endpoint of the treatment segment was at 6, and follow-up was at 10 weeks. The co-primary endpoints total inflammatory lesion count (TILC) and acne-specific Investigator Global Assessment (IGA) score as well as secondary endpoints sebumetry, total porphyrin count (TPC) reflecting Cutibacterium acnes colonization, and occurrence of adverse events (AEs) were measured from baseline until follow-up, while the Acne-specific Quality of Life (AQOL) questionnaire was assessed at baseline and endpoint. TILC decreased greater in the verum versus control group from baseline (45.8 vs. 49.4) toward endpoint (22.1 vs. 38.6; p = 0.07) to follow-up (16.5 vs. 28.7; p = 0.48), matched by the IGA score with similarly greater improvement in the verum versus control group from baseline (2.3 vs. 2.6) to endpoint (1.3 vs. 2.3; p <  0.001) until follow-up (1.0 vs. 1.9; p = 0.006). Sebumetry, TPC, and AQOL scores decreased more during treatment and in the verum group. AE occurred less frequently in the verum group without serious AE reported overall (all p < 0.05). Conclusively, CAP proved to be an efficient and well-tolerable add-on therapy for the treatment of mild acne papulopustulosa.

Trial Registration: German Registry of Clinical Trials: DRKS00032416

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Dermatologic Therapy
Dermatologic Therapy 医学-皮肤病学
CiteScore
7.00
自引率
8.30%
发文量
711
审稿时长
3 months
期刊介绍: Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.
期刊最新文献
Circulating Cytokine Levels and the Risk of Hypertrophic Scar: A Two-Sample Mendelian Randomization Study Efficacy and Safety of GR1802 in Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial The First Systematic Review and Meta-Analysis of Pharmacological and Nonpharmacological Procedural Treatments of Dark Eye Circles (Periorbital Hyperpigmentations): One of the Most Common Cosmetic Concerns The Efficacy and Safety of Combining Phototherapy and Topicals in the Treatment of Atopic Eczema: A Systematic Review of the Current Evidence Therapeutic Use of Cold Atmospheric Plasma for the Treatment of Mild Acne Papulopustulosa—A Randomized, Controlled, Double-Blind Pilot Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1